COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
Ivermectin study #54 of 63
1/19 Late treatment study
Rezai et al., IRCT20111224008507N3 (Preprint)
Effectiveness of Ivermectin in the Treatment of Coronavirus Infection in Patients admitted to Educational Hospitals of Mazandaran in 2020
Source   PDF   Share   Tweet
RCT in Iran showing shorter time to clinical recovery with Ivermectin.
Results are from: [1]

Rezai et al., 1/19/2021, Randomized Controlled Trial, Iran, Middle East, preprint, 1 author, dosage 200μg/kg single dose.
recovery time, 21.2% lower, relative time 0.79, p = 0.02, treatment 51, control 52.
hospitalization time, 17.9% lower, relative time 0.82, p = 0.01, treatment 51, control 52.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 63 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit